Mechanically, MCLA-145 functions by binding to PD-L1 on tumor cells and CD137 on T effector cells, facilitating the creation of an "immunological synapse." In this synapse, T cells can exposure to enhanced TCR signaling as PD-1 inhibition is relieved, and CD137 activation is intensified. Here, PDCD1 is linked to neoplasm.